RRP36 Inhibitors

Chemical inhibitors of RRP36 can exert their inhibitory effects through various mechanisms that impinge on the protein's role in rRNA processing. Actinomycin D, for example, inhibits RNA polymerase I, leading to a decrease in the synthesis of rRNA, which is essential for the maturation processes RRP36 is involved in. Similarly, by inhibiting RNA polymerase II, α-Amanitin can reduce the transcription of small nucleolar RNAs, which are critical for the modification and processing of rRNA, and subsequently influence the function of RRP36. Compounds like Camptothecin and Daunorubicin interfere with topoisomerase enzymes, resulting in DNA damage and disruptions that can affect the assembly of ribonucleoprotein complexes and the transcription of factors necessary for RRP36's function in RNA processing.

Further, chemicals like Bisphenol A can disrupt protein-protein interactions within ribonucleoprotein complexes, thereby potentially hindering RRP36's function. Mitomycin C forms DNA crosslinks that can impede transcription of RNA components vital to RRP36's role. Etoposide, another topoisomerase II inhibitor, disrupts transcription machinery that may be crucial for the production of non-coding RNAs or cofactors that RRP36 requires for efficient function. DNA-binding agents like Distamycin and Netropsin might disrupt transcription of snoRNAs or other rRNA processing factors, indirectly inhibiting RRP36. Triptolide, with its ability to disrupt transcription machinery, can lead to a reduction in the expression of non-coding RNAs or other cofactors necessary for RRP36's activity. Aflatoxin B1 causes DNA damage that results in transcriptional arrest, which can interfere with the biogenesis of RNA substrates or processing factors RRP36 depends on. Lastly, Novobiocin targets DNA gyrase, potentially affecting the transcription and maturation of rRNAs and other RNAs, thereby functionally inhibiting RRP36's role in the cell.